Indication
For the treatment of adult patients with relapsed or refractory (r/r) diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy.

Medicine details

Medicine name:
tisagenlecleucel (Kymriah)
SMC ID:
SMC2200
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Publication due date:
09 September 2019
SMC meeting date:
06 August 2019
Patient group submission deadline:
01 July 2019